Skip to main content
Menu

AlphaLISA Human PCSK9 Detection Kit, 500 Assay Points

The AlphaLISA™ Human Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) Detection Kit is designed for detection and quantitation of human PCSK9 in serum, buffered solution or cell culture medium in a homogeneous (no-wash steps, no separation steps) assay. One antibody targets the pro-domain of PCSK9.

Feature Specification
Application Protein Quantification
Dynamic Range 1,056 - 300,000 pg/mL
Limit of Detection 1,056 pg/mL  
Sample Volume 5 µL

The AlphaLISA™ Human Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) Detection Kit is designed for detection and quantitation of human PCSK9 in serum, buffered solution or cell culture medium in a homogeneous (no-wash steps, no separation steps) assay. One antibody targets the pro-domain of PCSK9.

Product variants
Unit Size: 500 assay points
Part #:
AL270C
List price
USD 2,463.76
Your online price:
Unit Size: 5,000 assay points
Part #:
AL270F
List price
USD 16,428.50
Your online price:
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption, and disposal requirements under European REACH regulations (EC 1907/2006).

Overview

Formats:

  • Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
  • Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

Features:

  • No-wash steps, no separation steps
  • ELISA alternative technology
  • Sensitive detection
  • Broad sample compatibility
  • Small sample volume
  • Results in less than 3 hours
  • Half the time of an ELISA assay

Human Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) belongs to the proteinase K subfamily of the secretory subtilase family. This glycoprotein contains 692 amino acids, including a signal peptide, a prodomain, and a catalytic domain. Initially synthesized as a soluble 74 kDa precursor protein, it is cleaved into 14 kDa and 60 kDa domains, which remain associated. This protein plays a major regulatory role in cholesterol homeostasis and is highly expressed in the kidney, liver, and intestine. PCSK9 binds to the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. Reduced LDLR levels result in decreased metabolism of low-density lipoprotein, which could lead to hypercholesterolemia. Inhibition of PCSK9 function is currently being explored as a means of lowering cholesterol levels. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia.

AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

How it works

Principle of the AlphaLISA assay

The AlphaLISA assay is based on an AlphaLISA sandwich immunoassay involving a biotinylated anti-analyte antibody bound to Streptavidin-coated AlphaLISA Donor beads and an anti-analyte antibody conjugated to AlphaLISA Acceptor beads. Both antibodies are directed against the analyte of interest. In the presence of the target, both antibodies bind to analyte and the beads come into proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer within the Acceptor beads, resulting in emission with λmax at 615 nm. The intensity of the signal is directly proportional to the concentration of analyte present in the sample.

Assay Principle AlphaLISA

 

Protocol of the AlphaLISA assay

The AlphaLISA assay can be run in a 96- or 384-well detection plate (50 µL final). As described here, samples or standards are dispensed directly into the assay plate for the detection of the analyte of interest by AlphaLISA reagents. No washing steps are needed. The protocol can be further miniaturized or upscaled by simply resizing each addition volume proportionally.

Protocol of the AlphaLISA human CCL17 assay

Specifications

Application
Protein Quantification
Automation Compatible
Yes
Brand
AlphaLISA
Detection Modality
Alpha
Dynamic Range
1,056 - 300,000 pg/mL
Limit of Detection
1,056 pg/mL  
Product Group
Kit
Sample Volume
5 µL
Shipping Conditions
Shipped in Blue Ice
Target
PCSK9
Target Class
Biomarkers
Target Species
Human
Technology
Alpha
Therapeutic Area
Cardiovascular
Unit Size
500 assay points

Video gallery

Resources

Are you looking for resources, click on the resource type to explore further.

1-1 of 1 Resources
Whitepaper Icon
Whitepaper
An overview of atherosclerosis

Atherosclerosis pathogenesis, cellular actors, and pathways

Atherosclerosis is a common condition in which arteries harden and...

Loading...

Scroll Icon

Revvity AI Assistant Beta